Clinical trials: Stage IV Cancer (Solid Tumors Only)
Stage IV Non-small Cell Lung Cancer, Stage IV Melanoma
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Sequential immune apheresis plasma volume escalation cohort study of reduction of soluble Tumor Necrosis Factors Receptors 1/2 (sTNFR1/2), with or without Nivolumab, in patients with inoperable or metastatic solid Tumors.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Stage IV Melanoma, Triple Negative Breast Cancer, Renal Cell Carcinoma Stage IV
- Trial name
- NCT04142931
- Testing
- ImmunicomAIAC
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Dr. Ronnie Shapira
Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread from where…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT02496208
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 8 sites in United States
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer
A Study of VET3-TGI in Patients With Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by…
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- STEALTH-001 (NCT06444815)
- Testing
- VET3-TGI, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- KaliVir Immunotherapeutics
Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
The purpose of this study is to determine if Itacitinib in combination with erlotinib is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB/Stage IV or recurrent whose tumors…
- Trial name
- NCT02355431
- Testing
- Itacitinib, erlotinib
- Where
- United States
- Sponsor
- Incyte Corporation
Unspecified Adult Solid Tumor, Protocol Specific
Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies
This phase I trial studies the side effects and best dose of Hsp90 inhibitor AUY922 in treating older patients with advanced solid malignancies.
- Trial name
- NCT01602627
- Testing
- Hsp90 inhibitor AUY922, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dale Shepard, MD, PhD
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
This is a prospective, single arm, phase Ib/IIa study. Up to 25 patients will be enrolled into the study (Part A: 2-18; Part B: 7-19).
- Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor, Metastatic Cancer, Adenocarcinoma of Lung
- Trial name
- AUTOMAN (NCT04770688)
- Testing
- Osimertinib, Anlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Chest Hospital
Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H)
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
- Trial name
- IGNYTE (NCT03767348)
- Testing
- RP1, nivolumab
- Where
- 51 sites in United States, France and 3 more
- Volunteers
- 340 people
- Sponsor
- Replimune, Inc.
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by…
- Conditions
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03217253
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma Stage IV, Solid Tumor
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy.
- Trial name
- NCT06425926
- Testing
- GIM-531, Anti-PD-1 monoclonal antibody
- Where
- 11 sites in United States
- Volunteers
- 117 people
- Sponsor
- Georgiamune Inc
Malignant Solid Tumors
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lung cancer,head and neck cancer,colorectal cancer,and ovarian cancer receiving multi-cycle chemotherapy.
- Trial name
- NCT02805166
- Testing
- PEG-rhG-CSF
- Volunteers
- 420 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma…
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03682289
- Testing
- Ceralasertib, Olaparib, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Rahul Aggarwal
Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system…
- Conditions
- Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis
- Trial name
- NCT03074513
- Testing
- Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT04721015
- Testing
- ABBV-637, Docetaxel, Osimertinib
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 81 people
- Sponsor
- AbbVie
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01638533
- Testing
- Pharmacological Study, Romidepsin
- Where
- 12 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
E7070 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of E7070 in treating patients who have solid tumors.
- Trial name
- NCT00003976
- Testing
- indisulam
- Where
- 27 sites in Austria, Belgium and 7 more
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT00369109
- Testing
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Stage IV Cancer (Solid Tumors Only), Survival
Observational Study of Survival Outcomes of Stage IV Cancer Patients
Patients diagnosed with Stage IV cancer (solid tumors only) are evaluated to determine whether they are candidates for traditional chemotherapy.
- Trial name
- NCT01843985
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Cure Cancer Worldwide Corporation
Stage IV Melanoma, Stage IV Renal Cell Cancer
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells.
- Conditions
- Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma
- Trial name
- NCT00019396
- Testing
- flt3 ligand, gp100 antigen, MART-1 antigen
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)